| Prev Close | 32.91 |
| Open | 32.96 |
| Day Low/High | 32.90 / 33.18 |
| 52 Wk Low/High | 28.82 / 46.24 |
| Volume | 46.16K |
| Avg Volume | 979.90K |
| Exchange | NASDAQ |
| Shares Outstanding | 68.44M |
| Market Cap | 2.26B |
| EPS | 0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Eligible Patients Can Use the myRisk® Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members
Provides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk® Hereditary Cancer Test
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 2,269,052 share decrease in total short interest for Myriad Genetics, Inc. , to 18,843,047, a decrease of 10.75% since 07/31/2017.
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.
Brings Total Coverage to Over 90 Percent of Breast Cancer Patients
Data from >800 Patients Shows that a High Vectra DA Score is Associated with an Increased Risk of Joint Damage and Is More Predictive than Conventional Measures of RA
Clinical Utility of Vectra® DA Further Demonstrated with New Data on Prediction of Joint Damage
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Myriad Genetics, Inc. , where a total of 5,567 contracts have traded so far, representing approximately 556,700 underlying shares.
Company to Seek FDA Approval of BRACAnalysis CDx Test in HER2- Metastatic Breast Cancer
Coverage Decisions Add 35 Million Additional Covered Lives Bringing Total to 109 Million
50 Percent of Mutations Were Found in Patients Who Do Not Meet Current Testing Guidelines; 34 Percent of Mutations Were Identified In Unexpected Genes
Prolaris Now Accessible to 70 percent of Medicare Patients with Prostate Cancer
Presentations Highlight Continued Advancements in Hereditary Cancer Panel Testing
Strong Predictive Power in Both African American and Non-African American Patients
Featured Study Will Show Power of the Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
26 Percent Discordance Rates Observed in Public Databases
Collaboration Will Evaluate Myriad's myChoice® HRD and BRACAnalysis CDx® Tests
